Shionogi, Purdue Pharma to Collaborate to Develop and Market New Analgesic Drug Compounds.Tokyo, Japan, Jan 11, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Shionogi and Purdue Pharma Purdue Pharma L.P., is privately-held pharmaceutical company founded by physicians. It is located in Stamford, Connecticut. Purdue is best known for painkillers, but they have also branched into other areas such as oncology and nutraceuticals. jointly announced on January 10 that they have concluded a multi-year agreement to develop and co-market new drug compounds for the treatment of pain. Specifically, the two companies will proceed with three research programs that focus on receptors and pathways known to modulate To insert a data signal into a carrier wave or direct current. See modulation. the pain response in the body, in order to discover compounds for analgesic analgesic (ăn'əljē`zĭk), any of a diverse group of drugs used to relieve pain. Analgesic drugs include the nonsteroidal anti-inflammatory drugs (NSAIDs) such as the salicylates, narcotic drugs such as morphine, and synthetic drugs drugs. Under the agreement terms, Shionogi will provide research expenses for the first three years and make milestone payments when the research programs accomplish certain results. In turn, Purdue Pharma will make certain milestone payments to Shionogi based on sales of commercialized products. The two companies will share the cost of clinical development. In addition, they plan to co-promote new agents created through this collaboration Working together on a project. See collaborative software. worldwide. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion